Funding
← Back to your selection

Sofinnova Partners

Activity from announced rounds

Activity in this selectionSeries B
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$281M
2 disclosed · full round size, not this investor’s share

By stage

Series B2

By primary sector

Biotech2

By country

United Kingdom1
United States1

Rounds

2 in this selection
Mironid

Mironid develops small-molecule medicines for inherited kidney disease, with a lead programme targeting autosomal dominant polycystic kidney disease.

$46MSeries B
Participant